NDT Pharmaceuticals Inc. (NDTP)
USD 0.07
(-58.27%)
USD 0.07
(-58.27%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 142.97 Thousand USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2017 | 50 Thousand USD | -0.13% |
| 2016 | 50.06 Thousand USD | -3.71% |
| 2015 | 51.99 Thousand USD | -62.68% |
| 2014 | 139.32 Thousand USD | 0.0% |
| 2010 | 329.83 Thousand USD | 0.0% |
| 2007 | 108.91 Thousand USD | 39.08% |
| 2006 | 78.31 Thousand USD | 777.24% |
| 2005 | 8927.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 142.97 Thousand USD | 0.0% |
| 2024 Q1 | 142.97 Thousand USD | 0.0% |
| 2023 Q3 | 142.97 Thousand USD | 0.0% |
| 2023 Q4 | 142.97 Thousand USD | 0.0% |
| 2023 FY | 142.97 Thousand USD | 0.0% |
| 2023 Q1 | 142.97 Thousand USD | 0.0% |
| 2023 Q2 | 142.97 Thousand USD | 0.0% |
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2017 FY | 50 Thousand USD | -0.13% |
| 2016 FY | 50.06 Thousand USD | -3.71% |
| 2015 FY | 51.99 Thousand USD | -62.68% |
| 2014 FY | 139.32 Thousand USD | 0.0% |
| 2011 Q1 | 315.08 Thousand USD | -4.47% |
| 2011 Q2 | 301.55 Thousand USD | -4.29% |
| 2010 Q1 | 362.16 Thousand USD | 0.0% |
| 2010 FY | 329.83 Thousand USD | 0.0% |
| 2010 Q4 | 329.83 Thousand USD | -2.6% |
| 2010 Q3 | 338.63 Thousand USD | -3.99% |
| 2010 Q2 | 352.7 Thousand USD | -2.61% |
| 2008 Q2 | - USD | -100.0% |
| 2008 Q1 | 187.69 Thousand USD | 72.33% |
| 2007 Q4 | 108.91 Thousand USD | -89.13% |
| 2007 Q3 | 1 Million USD | 22686.65% |
| 2007 Q2 | 4396.00 USD | -76.6% |
| 2007 Q1 | 18.78 Thousand USD | -76.01% |
| 2007 FY | 108.91 Thousand USD | 39.08% |
| 2006 Q2 | 2370.00 USD | -59.62% |
| 2006 Q3 | 97.75 Thousand USD | 4024.51% |
| 2006 Q4 | 78.31 Thousand USD | -19.89% |
| 2006 FY | 78.31 Thousand USD | 777.24% |
| 2006 Q1 | 5869.00 USD | 0.0% |
| 2005 FY | 8927.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -6089.264% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 92.699% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 98.645% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 74.105% |
| Rebus Holdings, Inc. | 5000.00 USD | -2759.44% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.89% |
| Qrons Inc. | 420.00 USD | -33940.952% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 81.448% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.488% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 70.249% |
| Skye Bioscience, Inc. | 11.94 Million USD | 98.803% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.632% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 98.02% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -87.249% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.867% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 90.016% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -97.571% |
| Mesoblast Limited | 667.9 Million USD | 99.979% |
| Marizyme, Inc. | 22.01 Million USD | 99.351% |
| Genus plc | 1.02 Billion USD | 99.986% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 89.475% |
| Pharming Group N.V. | 462.85 Million USD | 99.969% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 95.685% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 71.351% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 77.197% |
| ContraFect Corporation | 20.67 Million USD | 99.309% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 63.375% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 62.59% |
| IMV Inc. | 31.33 Million USD | 99.544% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 96.552% |
| MultiCell Technologies, Inc. | 126.22 USD | -113172.065% |
| ONE Bio Corp. | 70.08 Million USD | 99.796% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 84.785% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.889% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 66.883% |
| Q BioMed Inc. | 3.51 Million USD | 95.933% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.594% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 45.28% |
| Biomind Labs Inc. | 73.81 Thousand USD | -93.679% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.968% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 90.132% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.524% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 94.794% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 79.204% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 94.508% |
| GB Sciences, Inc. | 103.44 Thousand USD | -38.215% |
| Alpha Cognition Inc. | 2.45 Million USD | 94.17% |
| HST Global, Inc. | 1526.00 USD | -9269.069% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 85.529% |
| Halberd Corporation | 10.13 Thousand USD | -1311.233% |
| Enzolytics Inc. | 361.7 Million USD | 99.96% |
| Agentix Corp. | 261.39 Thousand USD | 45.304% |
| Resverlogix Corp. | 8.11 Million USD | 98.238% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 92.387% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.997% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.7% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 77.649% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -527.593% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 98.402% |
| AVAX Technologies, Inc. | 7.37 Million USD | 98.062% |
| Zenith Capital Corp. | 7410.00 USD | -1829.447% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.996% |
| Ember Therapeutics, Inc. | 184.00 USD | -77602.174% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 55.572% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 45.298% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 84.593% |
| Kadimastem Ltd | 2.3 Million USD | 93.795% |
| Helix BioMedix, Inc. | 3.02 Million USD | 95.274% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.729% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.018% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -150.415% |
| LadRx Corporation | 2.3 Million USD | 93.805% |
| Cell Source, Inc. | 195.17 Thousand USD | 26.745% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 59.569% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 59.569% |
| NovAccess Global Inc. | 62.24 Thousand USD | -129.681% |
| Affymax, Inc. | 7.44 Million USD | 98.079% |
| Itoco Inc. | 1.4 Million USD | 89.788% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -49.463% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -34.879% |
| Mobile Lads Corp. | 52.00 USD | -274846.154% |
| CytoDyn Inc. | 11.13 Million USD | 98.716% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -699.62% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 62.91% |
| SYBLEU INC | 330.46 Thousand USD | 56.737% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 65.08% |
| International Stem Cell Corporation | 5.39 Million USD | 97.347% |
| Bioxytran, Inc. | 137.63 Thousand USD | -3.875% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.047% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.138% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -80.977% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 83.465% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 98.098% |
| Neutra Corp. | 2851.00 USD | -4914.802% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.559% |
| PureTech Health plc | 693.97 Million USD | 99.979% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 98.229% |
| IXICO plc | 15.84 Million USD | 99.098% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 98.274% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.862% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.957% |